<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341428</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012303</org_study_id>
    <nct_id>NCT04341428</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate the Maintenance Effect of Treatment and Confirm the Safety of DWP14012 in Patients With Healed Erosive Esophagitis</brief_title>
  <official_title>A Multi-center, Double-Blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 as Maintenance Therapy in Patients With Healed Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the
      maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed
      erosive esophagitis confirmed on EGD after medication treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 24</measure>
    <time_frame>at 24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 12</measure>
    <time_frame>at 12 week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>GERD-Health related quality life(HRQL)</measure>
    <time_frame>at Weeks 4, 12, and 24</time_frame>
    <description>Changes from baseline in the total score of GERD-HRQL at Weeks 4, 12, and 24(The total score could range from 0 to 50 and lower score was evaluated as higher quality of life)</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment on symptoms</measure>
    <time_frame>Weeks 4, 12, and 24</time_frame>
    <description>Proportions of subjects without the major symptoms (heartburn and/or acid regurgitation) at Weeks 4, 12, and 24</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Healed Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 X mg</intervention_name>
    <description>DWP14012 X mg, tablet, orally, once daily for up to 24 weeks</description>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Xmg placebo</intervention_name>
    <description>DWP14012 Xmg placebo-matching tablet, orally, once daily for up to 24 weeks</description>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15 mg</intervention_name>
    <description>Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks</description>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15 mg Placebo</intervention_name>
    <description>Lansoprazole 15mg Placebo capsule, orally, once daily for up to 24 weeks</description>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female adults aged 19 to 75 years, at the date the written informed consent
             form is signed

          2. Subjects with erosive esophagitis (LA Grade A-D) confirmed on EGD within 12 weeks from
             Visit 2 (randomization day)

          3. Subjects with healed erosive esophagitis (no mucosal break observed according to LA
             classification) confirmed on EGD performed within 10 days before Visit 2
             (randomization day) after receiving the standard dose of medicinal products of erosive
             esophagitis (PPI, P-CAB, etc.) for 4 to 8 weeks for the treatment of erosive
             esophagitis

        Exclusion Criteria:

          1. Subjects who have Barrett's esophagus (&gt; 3 cm), gastroesophageal varix,
             esophagostenosis, ulcer stenosis, active peptic ulcer, acute gastrointestinal
             bleeding, or a malignant tumor upon EGD screening

          2. Subjects who have inflammatory bowel disease (Crohn disease, ulcerative colitis,
             etc.), irritable bowel syndrome (IBS), primary esophageal motility, or pancreatitis.

          3. Subjects with history of clinically significant disease of hepatic, renal, nervous,
             pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system

          4. Subjects who have had a malignant tumor in the last 5 years

          5. Subjects who must continue to take non-steroidal anti-inflammatory drugs (aspirin,
             etc.), antithrombotic drugs, etc. during the study period (A low dose of aspirin [100
             mg/day] which has been administered for prophylactic purpose before study entry is
             allowed)

          6. Subjects who cannot stop the existing erosive esophagitis treatment being taken
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oh-Young Lee</last_name>
    <phone>82-2-2290-8637</phone>
    <email>leeoy@hanyang.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JINIL KIM, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

